Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.660
0.00 (0.00%)
At close: Nov 20, 2026, 4:00 PM EST
2.650
-0.010 (-0.38%)
After-hours: Nov 20, 2026, 7:55 PM EST
Aytu BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 58.52 | 57.57 | 66.38 | 65.18 | 73.8 | 96.67 | |
Revenue Growth | -8.12% | -13.28% | 1.84% | -11.68% | -23.66% | 47.29% |
Cost of Revenue | 21.46 | 20.75 | 20.55 | 16.13 | 21.57 | 46.39 |
Gross Profit | 37.07 | 36.82 | 45.83 | 49.05 | 52.23 | 50.28 |
Selling, General & Admin | 45 | 42.64 | 38.29 | 42.04 | 49.77 | 69.88 |
Research & Development | - | - | 1.33 | 2.77 | 3.98 | 12.66 |
Amortization of Goodwill & Intangibles | 2.81 | 2.49 | 3.68 | 3.68 | 3.69 | 5.84 |
Operating Expenses | 47.81 | 45.13 | 43.29 | 48.49 | 57.44 | 88.39 |
Operating Income | -10.74 | -8.32 | 2.54 | 0.57 | -5.21 | -38.1 |
Interest Expense | -1.79 | -1.9 | -3.7 | -5.06 | -5.15 | -0.01 |
Other Non Operating Income (Expenses) | -7.55 | -4.02 | -2.22 | -3.13 | 5.22 | 0.86 |
EBT Excluding Unusual Items | -20.08 | -14.23 | -3.38 | -7.63 | -5.14 | -37.26 |
Merger & Restructuring Charges | - | - | -2.1 | -2.16 | - | - |
Impairment of Goodwill | - | - | - | - | - | -65.8 |
Asset Writedown | - | - | -8.26 | - | -2.73 | -7.66 |
Other Unusual Items | - | - | - | -0.59 | 0.58 | 1.82 |
Pretax Income | -20.08 | -14.23 | -13.75 | -10.38 | -7.29 | -108.89 |
Income Tax Expense | 0.02 | 0.02 | 0.44 | 2.14 | 0.26 | -0.11 |
Earnings From Continuing Operations | -20.1 | -14.25 | -14.18 | -12.52 | -7.55 | -108.78 |
Earnings From Discontinued Operations | - | - | 0.62 | -3.32 | -9.5 | - |
Net Income | -20.1 | -14.25 | -13.56 | -15.84 | -17.05 | -108.78 |
Net Income to Common | -20.1 | -14.25 | -13.56 | -15.84 | -17.05 | -108.78 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 15 | 12 | 6 | 6 | 3 | 1 |
Shares Outstanding (Diluted) | 15 | 12 | 6 | 6 | 3 | 1 |
Shares Change | 107.63% | 96.17% | 13.40% | 65.81% | 127.22% | 75.54% |
EPS (Basic) | -1.36 | -1.16 | -2.16 | -2.86 | -5.11 | -74.01 |
EPS (Diluted) | -1.36 | -1.16 | -2.16 | -2.86 | -5.11 | -74.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 3.6 | 3.25 | -2.17 | -1.72 | -5.13 | -28.82 |
Free Cash Flow Per Share | 0.24 | 0.26 | -0.34 | -0.31 | -1.54 | -19.61 |
Gross Margin | 63.34% | 63.95% | 69.04% | 75.26% | 70.77% | 52.02% |
Operating Margin | -18.35% | -14.44% | 3.82% | 0.87% | -7.05% | -39.42% |
Profit Margin | -34.34% | -24.76% | -20.43% | -24.31% | -23.11% | -112.53% |
Free Cash Flow Margin | 6.14% | 5.65% | -3.26% | -2.63% | -6.95% | -29.82% |
EBITDA | -6.49 | -4.39 | 7.91 | 7.29 | 2.49 | -27.96 |
EBITDA Margin | -11.10% | -7.62% | 11.92% | 11.18% | 3.38% | -28.92% |
D&A For EBITDA | 4.25 | 3.93 | 5.38 | 6.73 | 7.7 | 10.15 |
EBIT | -10.74 | -8.32 | 2.54 | 0.57 | -5.21 | -38.1 |
EBIT Margin | -18.35% | -14.44% | 3.82% | 0.87% | -7.05% | -39.42% |
Advertising Expenses | - | - | - | - | - | 13.6 |